A deep phenotyping approach to characterizing osteoarthritis progression
Active Grant Awarded
- Award ID
- R21AR082957
- Recipient
-
Michigan State University UEI NH77YPDEGG84
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $366,988
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 9% complete
- Place of performance
- East Lansing, MI 48824, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, through the National Institutes of Health's National Institute of Arthritis and Musculoskeletal and Skin Diseases, awarded Grant R21AR082957 to Michigan State University on September 17, 2026, with $366,988 obligated under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds a deep phenotyping study of osteoarthritis progression. The recipient will integrate symptoms, joint structure, physical activity, and their changes over time using Bayesian statistical modeling to define a latent quantitative trait (LQT) score representing osteoarthritis progression phenotypes. The LQT score will define individuals by their risk of progression, objectively assessed by the need for surgery. The study will also use the score to identify microRNAs that could serve as biomarkers, mechanistic drivers, and therapeutic targets. Preliminary data from the recipient's LQT, which integrated symptom and structure changes over eight years, showed that individuals who went on to have surgery had higher LQT scores over time.
The awardee operates as Henry Ford Health+Michigan State University Health Sciences. Place of performance is East Lansing, Michigan 48824. The period of performance runs from the September 17, 2026 award date to August 31, 2028. The assistance type is grant.
Description
- Abstract
- Osteoarthritis (OA) is a chronic, disabling condition affecting 7% of the global population, yet no disease-modifying OA drugs (DMOADS) are approved. Identifying patients at high risk of OA progression would enable targeted interventions to be developed to reduce the disease burden. Unfortunately, previous efforts to characterize OA progression have been based on either symptoms (e.g., pain, stiffness) or structure (e.g., cartilage loss, bone remodeling), but typically not both. A major challenge to consolidating these features is their discordance in OA over time. Additionally, environmental factors such as physical activity can impact OA progression, but have yet to be considered in phenotyping efforts. This points to an urgent need for novel methods to integrate multiple clinical factors into a unified OA phenotype that can be used for dmoad discovery. To meet this need, we propose a deep phenotyping approach that integrates symptoms, structure, physical activity, and their changes over time using bayesian statistical modeling to define a latent quantitative trait (LQT) that represents OA progression phenotypes. This LQT score will be used to define individuals by their risk for OA progression, objectively assessed by the need for surgery. IT will also be used to identify micrornas - small non-coding RNA molecules - that could serve as biomarkers and mechanistic drivers for the corresponding phenotype. Since micrornas regulate gene expression and can be readily modulated in vivo, they represent potential therapeutic targets. Similar bayesian modeling approaches have been successfully applied in other areas (e.g., cancer genomics) to identify patient subtypes. As preliminary data, we developed a LQT integrating OA symptom and structure changes over 8 years, and show individuals who go on to have surgery have higher LQT scores over time. Our primary objectives are to: I) integrate longitudinal symptom, structure, and environmental data into a LQT that represents OA progression phenotypes, and II) identify clinical outcomes (i.e., surgery) and epigenetic factors (i.e., micrornas) that are associated with the LQT. Our approach leverages the osteoarthritis initiative (OAI), a longitudinal cohort of 4,129 participants with or at risk for knee OA that includes data on structure (e.g., joint space), symptom (e.g., pain), and environmental (e.g., physical activity) factors. We hypothesize that defining a comprehensive OA progression phenotype with a LQT will enable more sensitive analyses of clinical outcomes and epigenetic factors than other UNI/multivariate clustering methods. This is significant because micrornas are epigenetic factors that can be therapeutically targeted to enable tailored intervention for OA. Our specific aims are to: 1) expand our LQT to capture structure, symptom, and environmental factors over time to describe an OA progression phenotype; and 2) identify micrornas associated with the LQT as potential biomarkers and mechanistic drivers of OA. The LQT is expected to represent validated OA progression phenotypes with both clinical and biological relevance. Micrornas associated with the LQT are expected to foster translational research aimed at improving OA prognostication and dmoad development.
Quick answers
Who received award R21AR082957?
R21AR082957 was awarded to Michigan State University by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on September 17, 2026.
How much is award R21AR082957 worth?
$366,988 has been obligated on R21AR082957.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award